FindTrial
Sign In

Subcutaneous Lenacapavir

DRUG4 trials

Sponsors

Gilead Sciences

Conditions

HIV-1 InfectionHIV-1-infection

Phase 1

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
CompletedNCT04811040
Gilead SciencesHIV-1 Infection
Start: 2021-04-08End: 2023-10-26Updated: 2025-01-27

Phase 2

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV
CompletedNCT04143594
Gilead SciencesHIV-1-infection
Start: 2019-11-22End: 2023-09-19Updated: 2024-10-02
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
Active, not recruitingNCT04150068
Gilead SciencesHIV-1-infection
Start: 2019-11-21End: 2027-01-01Updated: 2026-03-13
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
RecruitingNCT06749054
Gilead SciencesHIV-1-infection
Start: 2025-03-26End: 2027-04-30Target: 12Updated: 2025-12-02

Related Papers

Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab.
2026-01-01
P-365. Pooled safety and tolerability of twice-yearly lenacapavir with teropavimab and zinlirvimab for HIV-1 treatment
Open Forum Infectious Diseases2026-01-01
Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study.
2025-12-19
LENACAPAVIR: A NOVEL CAPSID INHIBITOR TRANSFORMING HIV MANAGEMENT
Zenodo (CERN European Organization for Nuclear Research)2025-11-30
LENACAPAVIR: A NOVEL CAPSID INHIBITOR TRANSFORMING HIV MANAGEMENT
Zenodo (CERN European Organization for Nuclear Research)2025-11-30
Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized study.
2025-10-07
Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab
The Journal of Infectious Diseases2025-03-304 citations
Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV
AIDS and Behavior2025-03-101 citations
P-590. Impact of Pharmacoenhancers on the Pharmacokinetics and Safety of Lenacapavir in People with HIV
Open Forum Infectious Diseases2025-01-29
155. Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study
Open Forum Infectious Diseases2025-01-29
Oportunidades no manejo de indivíduos com vírus da imunodeficiência humana altamente experientes no tratamento
Jornal de Assistência Farmacêutica e Farmacoeconomia2024-11-30
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.
2024-01-3031 citations
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
2023-07-1155 citations
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
2023-01-0173 citations
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
New England Journal of Medicine2022-05-11264 citations
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function.
Journal of Clinical Oncology2020-05-20